<option value="HUMHG01012" selected>HUMHG01012; LNCaP-1F5; Prostate epithelial cells derived from metastatic prostate carcinoma, genetically engineered to express rat glucocorticoid receptor, passages 15-35, parental</option>
<option value="HUMHG01014">HUMHG01014; LNCaP-1F5; Prostate epithelial cells derived from metastatic prostate carcinoma, genetically engineered to express rat glucocorticoid receptor, passages 15-35, siFoxA1</option>
<option value="HUMHG01211">HUMHG01211; PC-3; prostate cancer cells, Ethanol, wild-type AR</option>
<option value="HUMHG01212">HUMHG01212; PC-3; prostate cancer cells, Ethanol, SUMOylation-deficient AR</option>
<option value="HUMHG01213">HUMHG01213; PC-3; prostate cancer cells, 10 nM R1881, SUMOylation-deficient AR</option>
<option value="HUMHG01214">HUMHG01214; PC-3; prostate cancer cells, 10 nM R1881, wild-type AR</option>
<option value="HUMHG01234">HUMHG01234; VCaP; 10nM R1881 for 2hr, Vertebral Cancer of Prostate, bone metastasis of prostate cancer</option>
<option value="HUMHG01238">HUMHG01238; VCaP; 10nM R1881 for 2hr, siPIAS1, Vertebral Cancer of Prostate, bone metastasis of prostate cancer</option>
<option value="HUMHG01315">HUMHG01315; VCaP; NT</option>
<option value="HUMHG01317">HUMHG01317; VCaP; siERG</option>
<option value="HUMHG01319">HUMHG01319; 22RV1; no_treat</option>
<option value="HUMHG01320">HUMHG01320; LNCaP; 10 nM R1881 for 16 hr</option>
<option value="HUMHG01321">HUMHG01321; LNCaP; 1 nM R1881 for 48 hr</option>
<option value="HUMHG01322">HUMHG01322; LNCaP; hormone starved for 48 hours, ethanol control</option>
<option value="HUMHG01323">HUMHG01323; LNCaP; hormone starved for 48 hours, synthetic androgen R1881</option>
<option value="HUMHG01324">HUMHG01324; VCaP; hormone starved for 48 hours, ethanol control</option>
<option value="HUMHG01325">HUMHG01325; VCaP; hormone starved for 48 hours, synthetic androgen R1881</option>
<option value="HUMHG01330">HUMHG01330; metastatic prostate cancer tissue; Illumina Genome Analyzer</option>
<option value="HUMHG01596">HUMHG01596; LNCaP; Prostate cancer cell line, siCTRL, vehicle</option>
<option value="HUMHG01597">HUMHG01597; LNCaP; Prostate cancer cell line, siCTRL, DHT</option>
<option value="HUMHG01598">HUMHG01598; LNCaP; Prostate cancer cell line, siFoxA1, vehicle</option>
<option value="HUMHG01599">HUMHG01599; LNCaP; Prostate cancer cell line, siFoxA1, DHT</option>
<option value="HUMHG01608">HUMHG01608; prostate tumour; Human prostate tumour, untreated, sample ARM002</option>
<option value="HUMHG01609">HUMHG01609; prostate tumour; Human prostate tumour, untreated, sample ARM009</option>
<option value="HUMHG01610">HUMHG01610; prostate tumour; Human prostate tumour, untreated, sample NS018</option>
<option value="HUMHG01611">HUMHG01611; prostate tumour; Human prostate tumour, LHRH, Treatment-responsive(TR), sample NS013</option>
<option value="HUMHG01612">HUMHG01612; prostate tumour; Human prostate tumour, NA, Treatment-responsive(TR)</option>
<option value="HUMHG01613">HUMHG01613; prostate tumour; Human prostate tumour, HRPC, Castrate-resistant(CR), sample ARM003</option>
<option value="HUMHG01614">HUMHG01614; prostate tumour; Human prostate tumour, HRPC, Castrate-resistant(CR), sample NS020</option>
<option value="HUMHG01615">HUMHG01615; prostate tumour; Human prostate tumour, HRPC, Castrate-resistant(CR), sample NS012</option>
<option value="HUMHG01616">HUMHG01616; prostate tumour; Human prostate tumour, LHRH, Castrate-resistant(CR), sample NS019</option>
<option value="HUMHG01617">HUMHG01617; prostate tumour; Human prostate tumour, Castrate-resistant(CR), sample NS022</option>
<option value="HUMHG01618">HUMHG01618; 22Rv1; AR-stimulated</option>
<option value="HUMHG01619">HUMHG01619; LNCaP; androgen-dependent prostate cancer cell line, ethanol</option>
<option value="HUMHG01620">HUMHG01620; LNCaP; androgen-dependent prostate cancer cell line, DHT</option>
<option value="HUMHG01629">HUMHG01629; MDA-MB-453; breast cancer cell line, 10nM DHT for 4h</option>
<option value="HUMHG01630">HUMHG01630; MDA-MB-453; breast cancer cell line, 10nM DHT for 16h</option>
<option value="HUMHG01637">HUMHG01637; VCaP; prostate cancer cells, Hormone-depleted, 0hr treated</option>
<option value="HUMHG01638">HUMHG01638; VCaP; prostate cancer cells, Hormone-depleted, 2hr 100nM DHT treated</option>
<option value="HUMHG01639">HUMHG01639; VCaP; prostate cancer cells, Hormone-depleted, 18hr 100nM DHT treated</option>
<option value="HUMHG01676">HUMHG01676; LNCaP-1F5; Prostate epithelial cells derived from metastatic prostate carcinoma, genetically engineered to express rat glucocorticoid receptor, passages 15-35, rep1</option>
<option value="HUMHG01677">HUMHG01677; LNCaP-1F5; Prostate epithelial cells derived from metastatic prostate carcinoma, genetically engineered to express rat glucocorticoid receptor, passages 15-35, rep2</option>
<option value="HUMHG01796">HUMHG01796; VCaP; Hormone refractory prostate cancer cells, R1881 (1nM)</option>
<option value="HUMHG01797">HUMHG01797; VCaP; Hormone refractory prostate cancer cells, Vehicle (0.1% DMSO)</option>
<option value="HUMHG01798">HUMHG01798; VCaP; Hormone refractory prostate cancer cells, R1881 (1nM), Compound 30 (0.1uM)</option>
<option value="HUMHG01799">HUMHG01799; VCaP; Hormone refractory prostate cancer cells, R1881 (1nM), Compound 30 (1uM)</option>
<option value="HUMHG01800">HUMHG01800; VCaP; Hormone refractory prostate cancer cells, R1881 (1nM), Compound 30 (10uM)</option>
<option value="HUMHG01801">HUMHG01801; VCaP; Hormone refractory prostate cancer cells, R1881 (1nM), Compound 26 (0.1uM)</option>
<option value="HUMHG01802">HUMHG01802; VCaP; Hormone refractory prostate cancer cells, R1881 (1nM), Compound 26 (1uM)</option>
<option value="HUMHG01803">HUMHG01803; VCaP; Hormone refractory prostate cancer cells, R1881 (1nM), Compound 26 (10uM)</option>
<option value="HUMHG01896">HUMHG01896; LNCaP; control, shCtrl, Illumina HiScanSQ, biological replicate 1</option>
<option value="HUMHG01897">HUMHG01897; LNCaP; FoxA1 knockdown, shFoxA1, Illumina HiScanSQ, biological replicate 1</option>
<option value="HUMHG01918">HUMHG01918; LNCaP; control, shCtrl, hormone-deprived, Illumina HiScanSQ</option>
<option value="HUMHG01919">HUMHG01919; LNCaP; FoxA1 knockdown, hormone-deprived, shFoxA1, Illumina HiScanSQ</option>
<option value="HUMHG02003">HUMHG02003; LNCaP-1F5; 1000 nM CPA, Prostate epithelial cells derived from metastatic prostate carcinoma, genetically engineered to express rat glucocorticoid receptor, passages 15-35, repeat1</option>
<option value="HUMHG02004">HUMHG02004; LNCaP-1F5; 1001 nM CPA, Prostate epithelial cells derived from metastatic prostate carcinoma, genetically engineered to express rat glucocorticoid receptor, passages 15-35, repeat1</option>
<option value="HUMHG02005">HUMHG02005; LNCaP-1F5; 1000 nM RU486, Prostate epithelial cells derived from metastatic prostate carcinoma, genetically engineered to express rat glucocorticoid receptor, passages 15-35, repeat1</option>
<option value="HUMHG02006">HUMHG02006; LNCaP-1F5; 1001 nM RU486, Prostate epithelial cells derived from metastatic prostate carcinoma, genetically engineered to express rat glucocorticoid receptor, passages 15-35, repeat1</option>
<option value="HUMHG02007">HUMHG02007; LNCaP-1F5; Vehicle, Prostate epithelial cells derived from metastatic prostate carcinoma, genetically engineered to express rat glucocorticoid receptor, passages 15-35</option>
<option value="HUMHG02008">HUMHG02008; LNCaP-1F5; 1000 nM Bica, Prostate epithelial cells derived from metastatic prostate carcinoma, genetically engineered to express rat glucocorticoid receptor, passages 15-35</option>
<option value="HUMHG02010">HUMHG02010; VCaP; 100 nM DHT, Prostate epithelial cells derived from vertebral bone metastasis from patient with hormone refractory cancer, passages 15-35, repeat1</option>
<option value="HUMHG02011">HUMHG02011; VCaP; 101 nM DHT, Prostate epithelial cells derived from vertebral bone metastasis from patient with hormone refractory cancer, passages 15-35, repeat1</option>
<option value="HUMHG02013">HUMHG02013; VCaP; 100 nM DHT, Prostate epithelial cells derived from vertebral bone metastasis from patient with hormone refractory cancer, passages 15-35</option>
<option value="HUMHG02014">HUMHG02014; VCaP; 100 nM DHT+Dex, Prostate epithelial cells derived from vertebral bone metastasis from patient with hormone refractory cancer, passages 15-35</option>
<option value="HUMHG02225">HUMHG02225; MDA-MB-453; breast cancer,16h DHT treatment</option>
<option value="HUMHG02427">HUMHG02427; LNCaP; prostate cancer, Scrambled shRNA infection x3 days</option>
<option value="HUMHG02428">HUMHG02428; LNCaP; prostate cancer, ETV1sh2 infection</option>
<option value="HUMHG02443">HUMHG02443; DU145; prostate cancer cell line, AR wildtype</option>
<option value="HUMHG02444">HUMHG02444; DU145; prostate cancer cell line, AR wildtype + FoxA1</option>
<option value="HUMHG02445">HUMHG02445; DU145; prostate cancer cell line, AR wildtype + FoxA1 high</option>
<option value="HUMHG02451">HUMHG02451; DU145; prostate cancer cell line, AR C562S</option>
<option value="HUMHG02452">HUMHG02452; DU145; prostate cancer cell line, AR C562S +FoxA1</option>
<option value="HUMHG02453">HUMHG02453; DU145; prostate cancer cell line, AR Q640X</option>
<option value="HUMHG02454">HUMHG02454; DU145; prostate cancer cell line, AR Q640X+FoxA1</option>
<option value="HUMHG02455">HUMHG02455; DU145; prostate cancer cell line,AR G568W</option>
<option value="HUMHG02456">HUMHG02456; DU145; prostate cancer cell line,AR G568W+FoxA1</option>
<option value="HUMHG02459">HUMHG02459; LNCaP-ARmo; AR overexpression 2 - 4 fold, no DHT treatment</option>
<option value="HUMHG02460">HUMHG02460; LNCaP-ARmo; AR overexpression 2 - 4 fold, 1 nM DHT</option>
<option value="HUMHG02461">HUMHG02461; LNCaP-ARmo; AR overexpression 2 - 4 fold, 100 nM DHT</option>
<option value="HUMHG02462">HUMHG02462; LNCaP-ARhi; AR overexpression 5 - 6 fold, no DHT treatment</option>
<option value="HUMHG02463">HUMHG02463; LNCaP-ARhi; AR overexpression 5 - 6 fold, 1 nM DHT</option>
<option value="HUMHG02464">HUMHG02464; LNCaP-ARhi; AR overexpression 5 - 6 fold, 100 nM DHT</option>
<option value="HUMHG02465">HUMHG02465; LNCaP-pcDNA3.1; normal (control), no DHT treatment</option>
<option value="HUMHG02466">HUMHG02466; LNCaP-pcDNA3.1; normal (control), 1 nM DHT</option>
<option value="HUMHG02467">HUMHG02467; LNCaP-pcDNA3.1; normal (control), 100 nM DHT</option>
<option value="HUMHG02468">HUMHG02468; LuCaP73; xenografted tumor tissue, normal, no DHT treatment</option>
<option value="HUMHG02469">HUMHG02469; LuCaP69; xenografted tumor tissue, AR overexpression 10 fold, no DHT treatment</option>
<option value="HUMHG02638">HUMHG02638; LoVo; colon adenocarcinoma, ATCC CCL-229, FailedQC</option>
<option value="HUMHG03237">HUMHG03237; LNCaP; control, shCtrl, Illumina HiScanSQ, biological replicate 2</option>
<option value="HUMHG03238">HUMHG03238; LNCaP; FoxA1 knockdown, shFoxA1, Illumina HiScanSQ, biological replicate 2</option>
<option value="HUMHG03421">HUMHG03421; LNCaP; prostate cancer cells, DHT 10 nM for 24h</option>
<option value="HUMHG03424">HUMHG03424; VCaP; prostate cancer cells, siFOXA1, DHT 10 nM for 24h</option>
<option value="HUMHG03425">HUMHG03425; VCaP; prostate cancer cells, siFOXP1, DHT 10 nM for 24h</option>
<option value="HUMHG03426">HUMHG03426; VCaP; prostate cancer cells, siRUNX1, DHT 10 nM for 24h</option>
<option value="HUMHG03432">HUMHG03432; LNCaP; prostate cancer cells, DHT 10 nM for 24h</option>
<option value="HUMHG03433">HUMHG03433; VCaP; prostate cancer cells, DHT 10 nM for 24h</option>
<option value="HUMHG03434">HUMHG03434; VCaP; prostate cancer cells, ethanol (Vehicle) for 24h</option>
<option value="HUMHG03435">HUMHG03435; LNCaP; prostate cancer cells, DHT 10 nM for 24h</option>
<option value="HUMHG03438">HUMHG03438; LNCaP; prostate cancer cells, siFOXA1, DHT 10 nM for 24h</option>
<option value="HUMHG03758">HUMHG03758; LNCaP; prostate cancer cells, DHT 10 nM treatment, antibody AR</option>
<option value="HUMHG03759">HUMHG03759; LNCaP; siRUNX1, prostate cancer cells, DHT 10 nM treatment, antibody AR IIx</option>
<option value="HUMHG03784">HUMHG03784; LNCaP; 1h treatment with 100 nM DHT</option>